Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

Figure 1: Multiple myeloma – current and future market dynamics analysis
Figure 2: The author's assessment summary of key marketed and pipeline drugs for multiple myeloma
Figure 3: Multiple myeloma sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Sales of major multiple myeloma drugs in the US, Japan, and five major EU markets, by product, 2017-26
Figure 5: Combined sales of Darzalex, Empliciti, Ninlaro, and Kyprolis in the US, Japan, and five major EU markets, by drug, 2017-26
Figure 6: Sales of Darzalex and Empliciti in the US, Japan, and five major EU markets, by drug, 2017-26
Figure 7: Sales of Pomalyst and Kyprolis in the US, Japan, and five major EU markets, by drug, 2017-26
Figure 8: Sales of pipeline drugs in the US, Japan, and five major EU markets, by drug, 2017-26
Figure 9: Multiple myeloma sales across the US, Japan, and five major EU markets, by class, 2017–26
Figure 10: Patient-based forecast methodology for multiple myeloma
Figure 11: Price sources and calculations, by country
Figure 12: Darzalex for multiple myeloma – SWOT analysis
Figure 13: The author's drug assessment summary of Darzalex for multiple myeloma
Figure 14: The author's drug assessment summary of Darzalex for multiple myeloma
Figure 15: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 16: Empliciti for multiple myeloma – SWOT analysis
Figure 17: The author's drug assessment summary of Empliciti for multiple myeloma
Figure 18: The author's drug assessment summary of Empliciti for multiple myeloma
Figure 19: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 20: Farydak for multiple myeloma – SWOT analysis
Figure 21: The author's drug assessment summary of Farydak for multiple myeloma
Figure 22: The author's drug assessment summary of Farydak for multiple myeloma
Figure 23: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: Kyprolis for multiple myeloma – SWOT analysis
Figure 25: The author's drug assessment summary of Kyprolis for multiple myeloma
Figure 26: The author's drug assessment summary of Kyprolis for multiple myeloma
Figure 27: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 28: Ninlaro for multiple myeloma – SWOT analysis
Figure 29: The author's drug assessment summary of Ninlaro for multiple myeloma
Figure 30: The author's drug assessment summary of Ninlaro for multiple myeloma
Figure 31: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 32: Pomalyst for multiple myeloma – SWOT analysis
Figure 33: The author's drug assessment summary of Pomalyst for multiple myeloma
Figure 34: The author's drug assessment summary of Pomalyst for multiple myeloma
Figure 35: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 36: Revlimid for multiple myeloma – SWOT analysis
Figure 37: The author's drug assessment summary of Revlimid for multiple myeloma
Figure 38: The author's drug assessment summary of Revlimid for multiple myeloma
Figure 39: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 40: Thalomid for multiple myeloma – SWOT analysis
Figure 41: The author's drug assessment summary of Thalomid for multiple myeloma
Figure 42: The author's drug assessment summary of Thalomid for multiple myeloma
Figure 43: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 44: Treanda/Bendeka for multiple myeloma – SWOT analysis
Figure 45: The author's drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 46: The author's drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 47: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 48: Velcade for multiple myeloma – SWOT analysis
Figure 49: The author's drug assessment summary of Velcade for multiple myeloma
Figure 50: The author's drug assessment summary of Velcade for multiple myeloma
Figure 51: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 52: Venclexta for multiple myeloma – SWOT analysis
Figure 53: The author's drug assessment summary for Venclexta in multiple myeloma
Figure 54: The author's drug assessment summary for Venclexta for multiple myeloma
Figure 55: Venclexta sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 56: Ygalo for multiple myeloma – SWOT analysis
Figure 57: The author's drug assessment summary for Ygalo in multiple myeloma
Figure 58: The author's drug assessment summary for Ygalo for multiple myeloma
Figure 59: Ygalo sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
Figure 60: bb2121 for multiple myeloma – SWOT analysis
Figure 61: The author's drug assessment summary for bb2121 in multiple myeloma
Figure 62: The author's drug assessment summary for bb2121 in multiple myeloma
Figure 63: bb2121 sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
Figure 64: Isatuximab for multiple myeloma – SWOT analysis
Figure 65: The author's drug assessment summary for isatuximab in multiple myeloma
Figure 66: The author's drug assessment summary for isatuximab in multiple myeloma
Figure 67: Isatuximab sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 68: Selinexor for multiple myeloma – SWOT analysis
Figure 69: The author's drug assessment summary for selinexor in multiple myeloma
Figure 70: The author's drug assessment summary for selinexor in multiple myeloma
Figure 71: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 72: Multiple myeloma patient segmentation, by active and smoldering disease
Figure 73: Active multiple myeloma staging according to the R-ISS system, by country
Figure 74: Primary treatment options for smoldering multiple myeloma patients, by country
Figure 75: Top three pharmacological regimens used for smoldering multiple myeloma treatment, by country
Figure 76: Active SCT-eligible multiple myeloma patients receiving each line of therapy, by country
Figure 77: Active SCT-ineligible multiple myeloma patients receiving each line of therapy, by country
Figure 78: Top three regimens used for induction treatment of SCT-eligible multiple myeloma patients, by country
Figure 79: Consolidation therapy type for SCT-eligible multiple myeloma patients, by country
Figure 80: Top three pharmacological consolidation regimens used for SCT-eligible multiple myeloma patients, by country
Figure 81: Maintenance therapy type for SCT-eligible multiple myeloma patients, by country
Figure 82: Top three regimens used for pharmacological maintenance therapy alone in SCT-eligible patients, by country
Figure 83: Top three regimens used for pharmacological maintenance therapy after tandem autologous SCT, by country
Figure 84: Second-line therapy type for SCT-eligible multiple myeloma patients, by country
Figure 85: Top three pharmacological regimens used at second line for SCT-eligible multiple myeloma patients, by country
Figure 86: Third-line therapy type for SCT-eligible multiple myeloma patients, by country
Figure 87: Top three pharmacological regimens used at third line for SCT-eligible multiple myeloma patients, by country
Figure 88: Top three regimens used in fourth-line therapy for active SCT-eligible multiple myeloma patients, by country
Figure 89: Top three regimens used in fifth-line therapy and beyond for active SCT-eligible multiple myeloma patients, by country
Figure 90: Top three regimens used for induction treatment of multiple myeloma patients not eligible for SCT, by country
Figure 91: Top three regimens used for consolidation treatment of multiple myeloma patients not eligible for SCT, by country
Figure 92: Top three regimens used for maintenance treatment of multiple myeloma patients not eligible for SCT, by country
Figure 93: Top three pharmacological regimens used at second line for multiple myeloma patients not eligible for SCT, by country
Figure 94: Top three pharmacological regimens used at third line for multiple myeloma patients not eligible for SCT, by country
Figure 95: Top three regimens used at fourth line for multiple myeloma patients not eligible for SCT, by country
Figure 96: Top three regimens used at fifth line and beyond for multiple myeloma patients not eligible for SCT, by country
Figure 97: Trends in incident cases of multiple myeloma in the US, Japan, and five major EU markets, by country, 2017–37
Figure 98: Darzalex for multiple myeloma – SWOT analysis
Figure 99: The author's drug assessment summary of Darzalex for multiple myeloma
Figure 100: The author's drug assessment summary of Darzalex for multiple myeloma
Figure 101: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 102: Empliciti for multiple myeloma – SWOT analysis
Figure 103: The author's drug assessment summary of Empliciti for multiple myeloma
Figure 104: The author's drug assessment summary of Empliciti for multiple myeloma
Figure 105: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 106: Farydak for multiple myeloma – SWOT analysis
Figure 107: The author's drug assessment summary of Farydak for multiple myeloma
Figure 108: The author's drug assessment summary of Farydak for multiple myeloma
Figure 109: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 110: Kyprolis for multiple myeloma – SWOT analysis
Figure 111: The author's drug assessment summary of Kyprolis for multiple myeloma
Figure 112: The author's drug assessment summary of Kyprolis for multiple myeloma
Figure 113: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 114: Ninlaro for multiple myeloma – SWOT analysis
Figure 115: The author's drug assessment summary of Ninlaro for multiple myeloma
Figure 116: The author's drug assessment summary of Ninlaro for multiple myeloma
Figure 117: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 118: Pomalyst for multiple myeloma – SWOT analysis
Figure 119: The author's drug assessment summary of Pomalyst for multiple myeloma
Figure 120: The author's drug assessment summary of Pomalyst for multiple myeloma
Figure 121: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 122: Revlimid for multiple myeloma – SWOT analysis
Figure 123: The author's drug assessment summary of Revlimid for multiple myeloma
Figure 124: The author's drug assessment summary of Revlimid for multiple myeloma
Figure 125: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 126: Thalomid for multiple myeloma – SWOT analysis
Figure 127: The author's drug assessment summary of Thalomid for multiple myeloma
Figure 128: The author's drug assessment summary of Thalomid for multiple myeloma
Figure 129: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 130: Treanda/Bendeka for multiple myeloma – SWOT analysis
Figure 131: The author's drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 132: The author's drug assessment summary of Treanda/Bendeka for multiple myeloma
Figure 133: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country,2017–26
Figure 134: Velcade for multiple myeloma – SWOT analysis
Figure 135: The author's drug assessment summary of Velcade for multiple myeloma
Figure 136: The author's drug assessment summary of Velcade for multiple myeloma
Figure 137: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 138: Price sources and calculations, by country
Figure 139: Venclexta for multiple myeloma – SWOT analysis
Figure 140: The author's drug assessment summary for Venclexta in multiple myeloma
Figure 141: The author's drug assessment summary for Venclexta for multiple myeloma
Figure 142: Venclexta sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 143: Ygalo for multiple myeloma – SWOT analysis
Figure 144: The author's drug assessment summary for Ygalo in multiple myeloma
Figure 145: The author's drug assessment summary for Ygalo for multiple myeloma
Figure 146: Ygalo sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
Figure 147: bb2121 for multiple myeloma – SWOT analysis
Figure 148: The author's drug assessment summary for bb2121 in multiple myeloma
Figure 149: The author's drug assessment summary for bb2121 in multiple myeloma
Figure 150: bb2121 sales for multiple myeloma across the US and five major EU markets, by country, 2017–26
Figure 151: Isatuximab for multiple myeloma – SWOT analysis
Figure 152: The author's drug assessment summary for isatuximab in multiple myeloma
Figure 153: The author's drug assessment summary for isatuximab in multiple myeloma
Figure 154: Isatuximab sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 155: Selinexor for multiple myeloma – SWOT analysis
Figure 156: The author's drug assessment summary for selinexor in multiple myeloma
Figure 157: The author's drug assessment summary for selinexor in multiple myeloma
Figure 158: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26

Table 1: Multiple myeloma sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 2: Combined sales of Darzalex, Empliciti, Ninlaro, and Kyprolis in the US, Japan, and five major EU markets, by drug ($m), 2017-26
Table 3: Sales of Pomalyst and Kyprolis in the US, Japan, and five major EU markets, by drug ($m), 2017-26
Table 4: Sales of pipeline drugs in the US, Japan, and five major EU markets, by drug ($m), 2019-26
Table 5: Multiple myeloma sales across the US, Japan, and five major EU markets, by class and brand ($m), 2017–26
Table 6: Exchange rates used for calculating prices
Table 7: Medical oncologists and hematologists surveyed for the multiple myeloma primary research study, 2017
Table 8: Darzalex drug profile
Table 9: Darzalex pivotal trial data in multiple myeloma
Table 10: Darzalex early-phase trial data in multiple myeloma
Table 11: Darzalex Phase III trials in multiple myeloma
Table 12: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 13: Patients treated with Darzalex across the US, Japan, and five major EU markets, by country, 2017–26
Table 14: Empliciti drug profile
Table 15: Empliciti pivotal trial data in multiple myeloma
Table 16: Empliciti early-phase trial data in multiple myeloma
Table 17: Empliciti ongoing late-phase clinical trials in multiple myeloma
Table 18: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 19: Patients treated with Empliciti across the US, Japan, and five major EU markets, by country, 2017–26
Table 20: Farydak drug profile
Table 21: Farydak pivotal trial data in multiple myeloma
Table 22: Farydak early-phase trial data in multiple myeloma
Table 23: Farydak Phase II trial in multiple myeloma
Table 24: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 25: Patients treated with Farydak across the US, Japan, and five major EU markets, by country, 2017–26
Table 26: Kyprolis drug profile
Table 27: Kyprolis pivotal trial data in multiple myeloma
Table 28: Kyprolis late-phase trial data in multiple myeloma
Table 29: Kyprolis early-phase trial data in multiple myeloma
Table 30: Kyprolis ongoing Phase III trials in multiple myeloma
Table 31: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 32: Patients treated with Kyprolis across the US, Japan, and five major EU markets, by country, 2017–26
Table 33: Ninlaro drug profile
Table 34: Ninlaro pivotal trial data in multiple myeloma
Table 35: Ninlaro ongoing late-phase clinical trials in multiple myeloma
Table 36: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 37: Patients treated with Ninlaro across the US, Japan, and five major EU markets, by country, 2017–26
Table 38: Pomalyst drug profile
Table 39: Pomalyst pivotal trial data in multiple myeloma
Table 40: Pomalyst late-phase trial data in multiple myeloma
Table 41: Pomalyst key ongoing clinical trials in multiple myeloma
Table 42: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 43: Patients treated with Pomalyst across the US, Japan, and five major EU markets, by country, 2017–26
Table 44: Revlimid drug profile
Table 45: Revlimid pivotal trial data in multiple myeloma
Table 46: Revlimid ongoing clinical trials in multiple myeloma
Table 47: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 48: Patients treated with Revlimid across the US, Japan, and five major EU markets, by country, 2017–26
Table 49: Thalomid drug profile
Table 50: Thalomid pivotal trial data in multiple myeloma
Table 51: Thalomid late-phase trial data in multiple myeloma
Table 52: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 53: Patients treated with Thalomid across the US, Japan, and five major EU markets, by country, 2017–26
Table 54: Treanda/Bendeka drug profile
Table 55: Treanda early-phase trial data in multiple myeloma
Table 56: Patients receiving Treanda or generic bendamustine in the five major EU markets (%), by country
Table 57: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 58: Patients treated with Treanda/Bendeka across the US, Japan, and five major EU markets, by country, 2017–26
Table 59: Velcade drug profile
Table 60: Velcade pivotal trial data in multiple myeloma
Table 61: Velcade late-phase trial data in multiple myeloma
Table 62: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 63: Patients treated with Velcade in the US, Japan, and five major EU markets, by country, 2017–26
Table 64: Venclexta drug profile
Table 65: Venclexta Phase III trial in multiple myeloma
Table 66: Venclexta early-phase data in multiple myeloma
Table 67: Venclexta early-phase trials in multiple myeloma
Table 68: Venclexta sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 69: Patients treated with Venclexta in the US, Japan, and five major EU markets, by country, 2017–26
Table 70: Ygalo drug profile
Table 71: Ygalo Phase III trial in multiple myeloma
Table 72: Ygalo early-phase data in multiple myeloma
Table 73: Ygalo sales for multiple myeloma across the US and five major EU markets, by country ($m), 2017–26
Table 74: Patients treated with Ygalo in the US and five major EU markets, by country, 2017–26
Table 75: bb2121 drug profile
Table 76: bb2121 Phase II trial in multiple myeloma
Table 77: bb2121 early-phase data in multiple myeloma
Table 78: bb2121 sales for multiple myeloma across the US and five major EU markets, by country ($m), 2017–26
Table 79: Patients treated with bb2121 across the US and five major EU markets, by country, 2017–26
Table 80: isatuximab drug profile
Table 81: isatuximab Phase III trial in multiple myeloma
Table 82: Isatuximab Phase I/II data in multiple myeloma
Table 83: Isatuximab sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 84: Patients treated with isatuximab across the US, Japan, and five major EU markets, by country, 2017–26
Table 85: Selinexor drug profile
Table 86: Selinexor Phase III trial in multiple myeloma
Table 87: Selinexor early-phase data in multiple myeloma
Table 88: Selinexor sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 89: Patients treated with selinexor across the US, Japan, and five major EU markets, by country, 2017–26
Table 90: Medical oncologists and hematologists surveyed for the multiple myeloma primary research study, 2017
Table 91: Molecular subtypes of multiple myeloma
Table 92: Disease classification of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
Table 93: Common symptoms of multiple myeloma
Table 94: Co-morbidities associated with multiple myeloma
Table 95: International Staging System for multiple myeloma
Table 96: Durie-Salmon staging system for multiple myeloma
Table 97: The revised International Staging System criteria for multiple myeloma
Table 98: Leading treatments available for multiple myeloma across the US, Japan, and five major EU markets
Table 99: Time to progression from smoldering multiple myeloma to active multiple myeloma, by country
Table 100: Durie-Salmon, International Staging System (ISS), and revised ISS (R-ISS) staging classifications for multiplemyeloma
Table 101: Cancer registry databases used as a source of multiple myeloma incidence data, by country
Table 102: Forecasting methodology for multiple myeloma incidence, by country, age group, and gender
Table 103: Frequency of ultra high-risk characteristics among smoldering multiple myeloma patients
Table 104: Data sources for the Revised International Staging System distribution of multiple myeloma
Table 105: Data sources for immunoglobulin isotype distribution of multiple myeloma, by country
Table 106: Sources of survival data used to estimate multiple myeloma prevalence, by country
Table 107: Validation of forecast estimates against benchmark estimates
Table 108: Diagnosed incident cases of multiple myeloma in the US, Japan, and five major EU markets, by country, 2017–37
Table 109: Profiled key marketed drugs for multiple myeloma
Table 110: Darzalex drug profile
Table 111: Darzalex pivotal trial data in multiple myeloma
Table 112: Darzalex early-phase trial data in multiple myeloma
Table 113: Darzalex Phase III trials in multiple myeloma
Table 114: Darzalex sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 115: Patients treated with Darzalex across the US, Japan, and five major EU markets, by country, 2017–26
Table 116: Empliciti drug profile
Table 117: Empliciti pivotal trial data in multiple myeloma
Table 118: Empliciti early-phase trial data in multiple myeloma
Table 119: Empliciti ongoing late-phase clinical trials in multiple myeloma
Table 120: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 121: Patients treated with Empliciti across the US, Japan, and five major EU markets, by country, 2017–26
Table 122: Farydak drug profile
Table 123: Farydak pivotal trial data in multiple myeloma
Table 124: Farydak early-phase trial data in multiple myeloma
Table 125: Farydak Phase II trial in multiple myeloma
Table 126: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 127: Patients treated with Farydak across the US, Japan, and five major EU markets, by country, 2017–26
Table 128: Kyprolis drug profile
Table 129: Kyprolis pivotal trial data in multiple myeloma
Table 130: Kyprolis late-phase trial data in multiple myeloma
Table 131: Kyprolis early-phase trial data in multiple myeloma
Table 132: Kyprolis ongoing Phase III trials in multiple myeloma
Table 133: Kyprolis sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 134: Patients treated with Kyprolis across the US, Japan, and five major EU markets, by country, 2017–26
Table 135: Ninlaro drug profile
Table 136: Ninlaro pivotal trial data in multiple myeloma
Table 137: Ninlaro ongoing late-phase clinical trials in multiple myeloma
Table 138: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 139: Patients treated with Ninlaro across the US, Japan, and five major EU markets, by country, 2017–26
Table 140: Pomalyst drug profile
Table 141: Pomalyst pivotal trial data in multiple myeloma
Table 142: Pomalyst late-phase trial data in multiple myeloma
Table 143: Pomalyst key ongoing clinical trials in multiple myeloma
Table 144: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 145: Patients treated with Pomalyst across the US, Japan, and five major EU markets, by country, 2017–26
Table 146: Revlimid drug profile
Table 147: Revlimid pivotal trial data in multiple myeloma
Table 148: Revlimid ongoing clinical trials in multiple myeloma
Table 149: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 150: Patients treated with Revlimid across the US, Japan, and five major EU markets, by country, 2017–26
Table 151: Thalomid drug profile
Table 152: Thalomid pivotal trial data in multiple myeloma
Table 153: Thalomid late-phase trial data in multiple myeloma
Table 154: Thalomid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 155: Patients treated with Thalomid across the US, Japan, and five major EU markets, by country, 2017–26
Table 156: Treanda/Bendeka drug profile
Table 157: Treanda early-phase trial data in multiple myeloma
Table 158: Patients receiving Treanda or generic bendamustine in the five major EU markets (%), by country
Table 159: Treanda/Bendeka sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 160: Patients treated with Treanda/Bendeka across the US, Japan, and five major EU markets, by country, 2017–26 572 Table 161: Velcade drug profile
Table 162: Velcade pivotal trial data in multiple myeloma
Table 163: Velcade late-phase trial data in multiple myeloma
Table 164: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 165: Patients treated with Velcade in the US, Japan, and five major EU markets, by country, 2017–26
Table 166: Marketed multiple myeloma products and approved indications in the US, Japan, and five major EU markets
Table 167: Access levers for multiple myeloma treatments in the US and five major EU markets
Table 168: Pricing, market access, and reimbursement strategies for combination therapies
Table 169: Use of treatment algorithms and pathways to streamline prescribing within multiple myeloma across the US and five major EU markets
Table 170: Payer views on route of administration of multiple myeloma therapies
Table 171: Importance of multiple myeloma clinical trial endpoints in the US and five major EU markets
Table 172: Likely reimbursement of Darzalex in the front-line setting for transplant-ineligible multiple myeloma patients in the US and five major EU markets
Table 173: Reimbursement of Empliciti plus Rd in the second-line setting across the five major EU markets
Table 174: Reimbursement of Ninlaro plus Rd in the second-line setting across the five major EU markets
Table 175: Reimb